The board of China Pioneer Pharma Holdings Limited announced that with effect from 16 September 2022: Luo Chunyi has resigned as an executive Director and the authorised representative of the Company under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited in order to devote more time to his other personal commitments. Following the resignation of Luo, Mr. Li Xinzhou, the chairman of the Board and an executive Director, has been appointed as the Authorised Representative, with effect from 16 September 2022. The Board announced that with effect from 16 September 2022, Mr. Yang Yuewen has been appointed as an executive Director.

Yang Yuewen, aged 34, is the company's chief operating officer. Mr. Yang joined the Company in September 2016 and worked as a product manager and marketing manager of the AW business unit from September 2016 to September 2019. In October 2019, he was appointed as the general manager of the AW business unit of the Company and was responsible for the promotion and sales of Alfa Sigma's products and NovaBay's products of the Group.

Prior to joining the Company, Mr. Yang worked at Novartis Pharma Limited and AstraZeneca Pharma Limited. Mr. Yang graduated from Jiangxi University of Chinese Medicine with a bachelor's degree in pharmaceutical engineering in June 2010 and graduated from Jiangxi University of Chinese Medicine with a master's degree in pharmaceutical chemistry in June 2013 (the major was a joint training program between China State Institute of Pharmaceutical Industry and Jiangxi University of Chinese Medicine). He was appointed as the chief operating officer of the Company on 31 December 2021.

Mr. Yang has entered into a service contract with the Company for a term of three years commencing from 16 September 2022 and his appointment is subject to retirement by rotation and re-election at the general meetings of the Company in accordance with the articles of association of the Company.